


Docket No. 17120FWCCON6 (AP) 2  
Serial No. 10/621,195

In the Claims:

1. (Original) A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula II:



wherein the hatched segments represent α bonds, the solid triangle represents a β bond, wavy line attachments indicate either the alpha (α) or beta (β) configuration; dashed bonds represent a double bond or a single bond, R is a substituted heteroaryl radical, R<sup>1</sup> is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR<sup>1</sup>, -N(R<sup>1</sup>)<sub>2</sub>, and -N(R<sup>5</sup>)SO<sub>2</sub>R<sup>6</sup>, wherein R<sup>5</sup> represents hydrogen or CH<sub>2</sub>OR<sup>6</sup> and R<sup>6</sup> represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is =O or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.


2. (Original) The method of Claim 1 wherein the substituent on the heteroaryl radical is selected from the group consisting of lower alkyl, halogen, trifluoromethyl, COR<sub>1</sub>, COCF<sub>3</sub>, SO<sub>2</sub>NR<sub>1</sub>, SO<sub>2</sub>NH<sub>2</sub>, NO<sub>2</sub> and CN.

3. (Original) A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic

Docket No. 17120FWCCON6 (AP) 3  
Serial No. 10/621,195

solution in said container comprising a compound of formula I as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle.


4. (Original) A method of treating glaucoma which comprises administering to a mammal having glaucoma a therapeutically effective amount of a compound represented by formula I:



wherein the wavy segments represent either an alpha ( $\alpha$ ) or beta ( $\beta$ ) bond; dashed bonds represent a double bond or a single bond,  $R$  is a substituted hetero aryl radical,  $R^1$  is hydrogen or a lower alkyl radical having up to six carbon atoms,  $X$  is selected from the group consisting of  $-OR^1$ ,  $-N(R^1)_2$ ,  $R^1$  is hydrogen or a lower alkyl radical having up to six carbon atoms,  $X$  is selected from the group consisting of  $-OR^1$ ,  $-N(R^1)_2$ , and  $-N(R^5)SO_2R^6$ , wherein  $R^5$  represents hydrogen or  $CH_2OR^6$  and  $R^6$  represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical;  $Y$  is  $=O$  or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.


Docket No. 17120FWCCON6 (AP) 4  
Serial No. 10/621,195

5. (Original) The method of claim 4 wherein said compound is represented by formula II:



wherein the hatched segments represent  $\alpha$  bonds and the triangular segment represents a  $\beta$  bond.

6. (Original) A method of treating elevated intraocular pressure which comprises administering to a mammal having elevated intraocular pressure a therapeutically effective amount of a compound represented by formula I:




wherein the wavy segment represents either an alpha ( $\alpha$ ) or beta ( $\beta$ ) bond; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl

Docket No. 17120FWCCON6 (AP) 5

Serial No. 10/621,195

radical,  $R^1$  is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of  $-OR^1$ ,  $-N(R^1)_2$ ,  $R^1$  is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of  $-OR^1$ ,  $-N(R^1)_2$ , and  $-N(R^5)SO_2R^6$ , wherein  $R^5$  represents hydrogen or  $CH_2OR^6$  and  $R^6$  represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is  $=O$  or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.

7. (Original) The method of claim 6 wherein said compound is represented by formula II:



wherein the hatched segments represent  $\alpha$  bonds and the triangular segment represents a  $\beta$  bond.